Results from our recent Phase I/II pilot chemopreventive trial revealed that approximately one third of the trial participants were "high level responders" (1, 2) . As such, their premalignant oral lesions responded to topical application of a gel containing 10% w/w freeze dried black raspberries (BRB) (0.5 gm gel applied 4 times, total 2 gm daily) by improvement in all parameters assessed including histopathology, gene expression and reduction in loss of heterozygosity indices (1, 2) . The study design accommodated for the extensive inter-patient heterogeneity in oral dysplastic lesions by inclusion of pretreatment incisional biopsies to establish pretreatment baseline lesional parameters and provide a confirmed histopathologic diagnosis (1, 2) . The beneficial therapeutic responsiveness did not correlate with a lower baseline histologic grade as some of the optimal effects were obtained in persons with higher grade, previously recalcitrant-to-treatment dysplastic lesions (1, 2) . These findings imply that patientspecific differences in local pharmacokinetics i.e. target tissue absorption, metabolic bioactivation, and local retention of the BRB constituents affected chemopreventive responsiveness. Subsequent BRB gel pharmacokinetic analyses conducted in volunteers with healthy oral mucosa, which revealed extensive inter-participant differences with regard to gel absorption, distribution and local BRB compound retention, support this premise (3) .
Identification of the pharmacokinetic and metabolic parameters that modulate BRB gel effectiveness could help to optimize chemopreventive strategies. For example, if a BRB metabolite is determined to deliver enhanced chemopreventive effects, then subsequent formulations could incorporate the more bioactive metabolite instead of the parent compound.
This approach would provide equal therapeutic benefits to those patients with low bioactivating enzyme activities. Furthermore, identification of key therapy-modulating pharmacokinetic parameters such as absorption or tissue penetration could direct future topical agent formulations e.g. addition of penetration enhancing compounds. Finally, patient-specific pretreatment metabolic profiling, assessed relative to the identified BRB modulating parameters, could also be used to predict clinical outcomes. Supplemental strategies, such as introduction of additional chemopreventive compounds or different delivery systems, could then be employed on patients' lesions that show poor uptake and fail to bioactivate BRB chemopreventive compounds.
BRB, which served as the active agents in the gel, contain numerous compounds with potential chemopreventive activities, including anthocyanins, ellagic, ferulic, and p-coumeric acids, vitamins (ascorbic acid, Į and ȕ-carotene and folate), and minerals (4) . It is, however, the BRB anthocyanins i.e. cyanidin 3-rutinoside, cyanidin 3-xylosylrutinoside, cyanidin 3-glucoside and cyanidin 3-sambubioside, which comprise the predominant (3 to 5% BRB weight) polyphenolic bioassay results (7) . Due to their obvious importance in BRB chemoprevention, anthocyanin metabolism is the focus of this study.
Deglycosylation of the parent BRB anthocyanin to its respective aglycone enhances chemopreventive impact by removing the bulky sugar groups which could cause steric hindrance, replacing the glucosidic linkage by another antioxidant-scavenging hydroxyl group and facilitating transport independent cell uptake (8) . Previous studies by Walle et al. demonstrated that human saliva and oral microflora generate aglycones from intact flavonoid glycosides e.g. genisten, with ȕ-glucosidase representing the key responsible enzyme (9) . Additional studies by Fleschhut et al. showed that gastrointestinal flora not only metabolize monoglycosylated anthocyanins (such as the recognized less stable cyanidin 3-glucoside) but also deglycosylate the more complex diglycosylated and acetylated anthocyanins (10) . In addition to deglycosylation, anthocyanins can be metabolized by Phase II enzymes [UDP-glucuronosyl transferases (UGTs) and sulfotransferases (SULTs)] and also undergo methylation via catechol-O-methyltransferase (11) . Phase II enzymes are typically associated with enhancing solubility to facilitate compound elimination. Recent investigations by Hu et al., which imply that Phase II metabolites of flavonoids undergo enteric recycling within the gastrointestinal tract, suggest an expanded role for Phase II enzymes (12, 13) . Oral mucosal anthyocyanin recycling would augment chemopreventive efficacy by increasing contact time of the BRB chemopreventives with the target premalignant oral epithelial cells. As the mouth is contiguous with the more distal components of the gastrointestinal tract, oral cavity enteric recycling is logical and plausible.
Potential contributors to intraoral anthocyanin metabolism include oral tissues, saliva, and oral microflora. Accordingly, this study investigated the effects of these oral components on parameters likely to modulate BRB anthocyanins' chemopreventive efficacy. Tissue analyses included a comprehensive profiling of enzymes of interest that could affect anthocyanin bioactivation and local intraoral levels. Saliva and oral microflora contributions to anthocyanin metabolism were assessed via pharmacokinetic analyses of three different BRB rinse formulations as well as functional activity assays. Collectively, our data support the prospect that enteric recycling of anthocyanins occurs in the mouth. Furthermore, inter-patient variations in the extent of this process could directly impact the effects of locally delivered chemopreventives.
Materials and Methods
Participation of human subjects. Human subject participation in these studies was in accordance with Ohio State University Institutional Review Board approval and followed the tenets of the Declaration of Helsinki 1964. Ten clinically healthy, nonsmoking volunteers between the ages of 19 to 61 participated in the rinse study. These same 10 individuals plus an additional participant provided saliva samples for the functional ȕ-glucosidase activity assay. This eleventh saliva donor was also a non-smoking, clinically healthy male aged 30. Fifteen donor tissues, obtained from 15 consented individuals undergoing elective oral maxillofacial surgical procedures were employed for the enzyme metabolic profiling studies by Western blot analyses. As only 10 of the tissues employed for immunoblotting contained adequate tissue for immunohistochemical analyses (IHC), five additional clinically normal oral tissues for the IHC studies were obtained from consented donors. All human subjects participants had uncomplicated medical histories which were characterized by no hospitalizations with the exception of elective procedures, ASA PS1 health status, healthy oral tissues and no mucosal or intrabony pathologies.
Preparation of the BRB rinse formulations. Three BRB rinse formulations were evaluated in this study (See Table 1 for description of the three rinses). All constituents were pharmaceutical grade, and the rinses were prepared fresh on the day of the assay under a laminar flow sterile hood. Rinses were prepared with the same amount of BRB (10% w/w) that was used in our gel formulation (See Table 1 ). (1) (2) (3) . Rinse II also included chlorhexidine gluconate (0.12% final concentration). Chlorhexidine gluconate persists in human saliva for at least 12 hours after rinsing (14, 15) and its intraoral sustainability is felt to reflect the cationic salt's absorption to oral surfaces (14, 15) . The purpose for chlorhexidine inclusion was to determine whether or not chlorhexidine could augment BRB absorption and sustainability. Secondly, as chlorhexidine gluconate is antibacterial, inclusion of chlorhexidine gluconate permitted determination of the relative contribution of salivary and oral tissue metabolizing enzymes in the presence of reduced amounts of oral microflora.
BRB Rinse Pharmacokinetic Analyses. In this crossover study, ten participants rinsed with all three preparations, with a seven day "wash out" period between the testing of different rinse Immunoreactions were visualized using the DAB substrate, followed by hematoxylin counterstaining. Images were captured using a Nikon DS-Fi-1 high-resolution digital camera and analyzed using Image-Pro Plus 6.2 software (Media Cybernetics, Bethesda, MD, USA). IHC negative controls consisted of the exclusive addition of secondary antibody in the absence of primary antibody. 
Detection of residual glucuronidated

Statistical Analyses.
The Kruskal-Wallis ANOVA, followed by the Dunns' Multiple
Comparison test, was used to evaluate the anthocyanin levels at respective time points in the donor population as a whole. Assessment of individual donor responsiveness to the respective rinses i.e. which rinse provided the highest intra-donor levels of the parent anthocyanin at time PCA. The effects of chlorhexidine gluconate on salivary ȕ-glucosidase activities were assessed via the chi square one-way classification. The normality of the data distribution determined whether parametric or nonparametric analyses were utilized. Findings with p values < 0.05 were considered significant.
Results
BRB rinses provide sustained levels of BRB anthocyanins in saliva and demonstrate inter-rinse differences. Post-rinse anthocyanin levels showed rinse-related differences, with saliva collected following Rinse I containing the highest levels of BRB parent anthocyanins over the time course of the study. Inter-donor differences in salivary anthocyanin levels were also apparent. The greatest inter-donor variability was noted at the early (0, 5 and 30 minutes) time points, and most apparent in the cyanidin 3-rutinoside (predominant BRB anthocyanin) and protocatechuic acid (stabilized metabolite) samples. Average inter-donor early time point differences were 5 fold, with ranges from 3.6 to 10.3 fold. Inter-rinse comparisons demonstrated that Rinse I provided significantly higher (p 0.05) BRB anthocyanin levels relative to Rinse III at several time points: time 0 (cyanidin 3-rutinoside, cyanidin 3-glucoside, cyanidin 3-sambubioside), 30 minutes (cyanidin 3-xylosylrutinoside, cyanidin 3-sambubioside), 60 minutes (cyanidin 3-xylosylrutinoside), 240 minutes (cyanidin 3-rutinoside, cyanidin-3 xylosylrutinoside, cyanidin-3 sambubioside). These significant differences were detected in both the inter-donor and intradonor comparisons. Rinse II anthocyanin levels were only significantly lower than Rinse I at one time point: time 0, cyanidin-3 glucoside, for both inter and intra donor comparisons. As would be anticipated, levels of all measured compounds decreased over time e.g. rutinoside levels in saliva ranged from a high (mean ± S.D.) 2287.12 ± 489.55 ȝg/ml at initial time point (Rinse I) to 0.05 ± 0.06 ȝg/ml at the final (240 minute) time point (Rinse III). Overall, parent BRB anthocyanins showed the greatest decrease in Rinse III over time. In addition, Rinse III, which contained the food-mimic sweeteners but not the antimicrobial chlorhexidine gluconate, showed the highest levels of anthocyanin metabolism and/or degradation. Finally, while early (up to 5 minute post rinse) saliva samples obtained from all three rinse groups showed detectable levels of the aglycone, cyanidin, in all donors, cyanidin levels rapidly decreased and were undetectable in all samples from all rinses by 60 minutes (data not shown). 
BRB rinses provide significantly higher levels of salivary anthocyanins relative to the BRB gel.
Previous studies have confirmed that saliva is the intraoral compartment that retains the highest BRB anthocyanin levels following topical intraoral gel application (3). Gel to BRB rinse comparisons of salivary levels of cyanidin 3-rutinoside (most prevalent BRB anthocyanin) and total anthocyanins (collective chemopreventive compounds) were therefore performed at all shared saliva collection time points (5, 60, 120 and 240 minutes). BRB rinses provided higher salivary levels of both total BRB anthocyanins as well as the predominant anthocyanin (cyanidin-3 rutinoside) relative to topical gel application (Figure 1.A. and 1.B.) . Notably, 9 of 10 participants retained detectable rutinoside levels at 240 minutes (Rinses I and III), and 10 out of 
samples (including oral microflora, 80 fold) as well as after rinsing with chlorhexidine gluconate (38-fold).
Results from the Western blots and IHC analyses of oral mucosal tissues confirmed the presence of ȕ-glucosidase protein in human oral mucosa. Western blots also confirmed that all 15 tissues analyzed contained modest to high (18% to 66% of control protein) levels of ȕ-glucosidase with a 3.7 fold inter-donor protein level differences observed ( Table 2) . Complementary IHC analyses to identify the sites for cellular distribution revealed ȕ-glucosidase is concentrated in the spinous and granular layers of stratified squamous surface epithelium. Notably, while salivary gland acini and intercalated ducts were negative, terminal salivary ducts demonstrated intense staining for ȕ-glucosidase (Figure 2) . These data imply that the non-microbial ȕ-glucosidase reflects contributions of both saliva as well as enzyme release into saliva from both the surface epithelium and the terminal ducts through which saliva passes en route to the surface.
Oral mucosal tissues possess moderate to high levels of the enzymes that are requisite for flavonoid enteric recycling. Table 2 
Glucuronidated anthocyanin conjugates are detectable in post BRB rinse saliva samples.
To enhance the sensitivity of monitoring for the presence of glucuronidated anthocyanins in these saliva samples, the expected ions of these anticipated glucuronidates of at the following m/zs were monitored. As shown in Figure 3 (Figure 3.A.ii.) , but absent in the original Rinse III solution (Figure 3.A.i.) . Also, the tandem mass spectra of Peak I and II provide the two expected product ions of m/z 449 and 287 (Figure 3.A.iii. and 3.A.iv.) . These results imply that the components of these two peaks are cyanidin-3 sambubioside glucuronides. Further confirmation of these data was obtained following incubation of cyanidin-3 sambubioside with rat liver microsomes, which generated cyanidin-3 sambubioside glucuronides with the similar retention time and tandem mass spectra as previously reported (18) . The tandem mass spectrum of Peak III showed a single peak of m/z 757.37 ( These data are consistent with a recently reported mass spectrum of PCAOG (19) . The data dependent collision-induced dissociation spectrum (Figure 3.C.ii.) 
Discussion
Determination of chemopreventive compound levels achieved at the treatment site and correlation between lesional tissue metabolism and therapeutic efficacy are not currently assessed in chemoprevention trials. These aspects, however, are likely among the prime effectors that determine chemopreventive outcomes. The goal of this study was therefore to characterize the oral cavity's anthocyanin-relevant metabolic enzyme profile and to evaluate in situ anthocyanin metabolism.
The entire oral mucosa of persons who develop oral cancer is speculated to have undergone field cancerization (20) . Oral cancer chemopreventive strategies should therefore incorporate formulations which address both site-specific and field coverage components. A topical agent plus rinse combination, which would deliver high intra-lesional levels and also disperse chemopreventives throughout the mouth, would fulfill these requirements. Consequently, the purpose of the BRB rinse studies was two-fold i.e. assess human oral mucosal anthocyanin metabolism and determine if rinses can provide sustainable chemopreventive levels in the mouth.
Formulation-associated differences in post-rinse salivary BRB anthocyanin levels were noted. salivary anthocyanin levels. These data suggest that rinses perceived as food stimulated release of saliva and associated salivary ȕ-glucosidase, thereby increasing anthocyanin deglycosylation.
Recorded salivary volumes, which showed higher saliva volumes in the Rinse II and III samples, support this premise (data not shown). As these data reflect total anthocyanins and account for saliva volumes, the differences don't reflect volume dilutions in the Rinse II and III samples. Ideally, locally delivered chemopreventives persist at the treatment site. While the saliva data confirmed BRB retention, the real question is whether these levels are clinically relevant.
Previous studies have confirmed that the BRB topical gel elicited chemopreventive effects (1, 2) and that the highest levels of the parent BRB anthocyanins were detected in saliva (3). Post-rinse BRB salivary anthocyanin levels were therefore compared to salivary levels achieved following gel application. All of the rinses delivered higher salivary BRB anthocyanin levels at the initial time point, and also provided greater sustainability over time relative to levels achieved with gel application. The mechanism of rinse-mediated anthocyanin retention is under investigation. For example, chlorhexidine gluconate interacts with salivary films, and adsorbs to teeth and oral mucosal surfaces (14, 21) . Local adsorption enables retention of approximately 30% of chlorhexidine gluconate, which is then slowly released over time (21) . Although BRB anthocyanins are structurally distinct from chlorhexidine gluconate, the post-rinse data, which show sustained salivary levels of anthocyanins, suggest that BRB anthocyanins may also be adsorbed to oral tissues and/or oral microflora present in plaque. Notably, although the rinses and gel both contained the identical 10% BRB concentration, the larger rinse volume delivered a greater amount of BRB per dose. 
identified (23). Our findings, which demonstrate ȕ-glucosidase protein in human oral mucosa by immunoblotting and confirm the presence of both ȕ-glucosidase and LPH localization in surface oral epithelium by immunohistochemistry, clarify the distribution of these relevant metabolic enzymes in human oral tissues. These findings confirm that oral microflora, salivary enzymes and oral epithelium can all contribute to generation of the bioactive aglycone from parent anthocyanins.
The strong correlation between smoking and alcohol use and the development of oral cancer implies that the mouth is an active site for xenobiotic metabolism. Intraoral xenobiotic enzyme characterization studies to date, however, have focused at the transcriptional level (24) .
Consequently, little is known regarding inter-donor variations in protein levels and in which cell population(s) the enzymes are distributed. Our protein profiles of clinically and histologically normal oral mucosa demonstrated that the majority of the metabolic and recycling enzymes necessary for anthocyanin enteric recycling were present in every oral tissue specimen evaluated.
Furthermore, enzyme distribution, as determined by IHC analyses, confirmed the relevant enzymes were almost exclusively distributed within the stratified squamous surface epithelium or within the terminal salivary ducts i.e. target tissues. Also apparent were the fairly extensive interdonor differences in levels of enzyme present (ranging from 3.5 to 63 fold) and enzyme activities (over 30 fold differences in ȕ-glucosidase function). Finally, two additional key enzymes essential for recycling of Phase II anthocyanin conjugates i.e. ȕ-glucuronidase and arylsulfatase, are known to be present in human saliva (17).
Although detection of the necessary bioactivating, Phase II and efflux transporter enzymes in human oral tissues supports the feasibility for intraoral anthocyanin enteric recycling, their mere presence does not confirm ongoing activity. The detection of glucuronidated anthocyanin-derived conjugates in saliva implies anthocyanin epithelial uptake, metabolism, and release of a stabilized metabolite capable of undergoing recycling via deglucuronidation and cellular re-entry ( Figure   4 ). As UGTs are present in organisms ranging from bacteria to humans, conceptually the detected conjugate could reflect oral bacteria-associated glucuronidation and not entail intracellular uptake, glucuronidation and egress via UGT-efflux transporters (25) . Notably, results obtained from the ex-vivo saliva-BRB incubations, which did not reveal any glucuronidated conjugates in whole saliva without the addition of exogenous liver microsomal enzymes, imply that the requisite UGT1A activity does not exist in saliva. Furthermore, gastrointestinal microflora- 
glucuronidase. Detection of a glucuronidated conjugate is therefore consistent with anthocyanin epithelial uptake (26) , metabolism, and release of a metabolite capable of undergoing recycling via deglucuronidation and cellular re-entry (Figure 4) . Cyanidin-3 sambubioside, which is found in relatively low levels in BRB (5, 7), was the exclusive glucuronidated anthocyanin conjugate identified. Di and triglycosylated anthocyanins are more stable than the monoglycosylated forms and are therefore present at higher levels (4, 5) . Furthermore, as enteric recycling is a dynamic process, all glucuronidated species are likely present in small quantities and for a very transient time.
Interestingly, our data also confirmed the presence of a PCA-glucuronide. These data are consistent with findings by Woodward et al., which imply that PCA glucuronides represent a predominant anthocyanin species following simulated gastrointestinal digestion (18) . Our data imply that the major glucuronidated PCA isomer is formed shortly after rinsing and provide the proof of concept that PCA glucuronides are generated intraorally after anthocyanin administration. Studies to elucidate the intraoral glucuronidation kinetics of intraoral anthocyanin and related compounds are ongoing.
Enterohepatic recycling is a well-accepted mechanism by which parent compounds and their metabolites re-enter systemic circulation following first-pass metabolism in the liver. For many tissues and organs e.g. breast, prostate, this is the exclusive route by which exposure to chemopreventives occurs. In contrast, gastrointestinal mucosa, which is in direct contact with orally administered agents, avoids first pass metabolism by the liver and directly absorbs, bioactivates and metabolizes chemopreventives (27) . The requisite components that enable Although glucuronidation is presumed to be the primary route for anthocyanin Phase II metabolism (29) , the requisite components for other routes of anthocyanin metabolism e.g. methylation or glutathionylation (COMT and glutathione, respectively) are also present in oral mucosa. Similar to glucuronic acid, conjugation with methyl groups or glutathione could also affect anthocyanin stability and local retention. Notably, inter-patient differences in anthocyanin bioactivation and enteric recycling would impact treatment as retention of bioactivated chemopreventives at the target site would sustain therapeutic effectiveness. Pretreatment metabolic profiling of key anthocyanin bioactivating and enteric recycling enzymes and local pharmacokinetics could potentially be used to predict patients most likely to respond favorably to an anthocyanin-based chemopreventive. Such studies are currently ongoing as a component of our BRB gel chemoprevention trial. At the conclusion of the trial, pretreatment profiles will be compared to post treatment effects to determine the "predictive potential" of anthocyanin metabolic profiles with prospective clinical outcomes. Its composition is: water (97%), sodium phosphate monobasic (<1%), sodium carboxymethylcellulose (<1%), microcrystalline cellulose (<1%), xanthan gum (<1%), carrageenan (<1%). Any other ingredients are <0.1% and are considered GRAS. This vehicle is frequently used in pediatric pharmaceutical preparations.
Ora-Sweet SF™:
This is a sugar and alcohol-free oral syrup vehicle, manufactured by Paddock Laboratories, which is used to provide a sweet fruity odor and taste to liquid medications. Its component ingredients are: sorbitol (10%), glycerin (9%), and sodium saccharin (0.1%). Ora-Sweet SF™ is used in conjunction with Ora-Plus™ in the preparation of liquid pediatric pharmaceutical preparations.
Glycerin: This is a GRAS compound that is used as an antimicrobial, preservative emollient. Glycerin was included in the enhanced rinse formulations to augment rinse viscosity and therefore increase opportunity for the adherence of BRB compounds to oral mucosal tissues.
Chlorhexidine gluconate: This is the antimicrobial agent used in oral health care products for treatment of periodontal disease e.g. Peridex®, Gum® chlorhexidine gluconate oral rinse. Chlorhexidine gluconate has been shown to demonstrate substantivity in the mouth (approximately 30% of chlorhexidine is retained in the oral cavity following rinsing), with the retained drug slowly being released into oral fluids. Chlorhexidine gluconate's substantivity is felt to reflect binding of this positively charged compound to negative charges located on oral mucosal tissues.
Pharmacokinetics of chlorhexidine gluconate. Following rinsing, approximately 30% of chlorhexidine gluconate is retained in the oral cavity, and the retained compound is slowly released into oral fluids. This compound is poorly absorbed from the gastrointestinal tract, with the mean peak plasma levels of chlorhexidine gluconate obtained at 30 minutes (0.206 ȝg/g) after ingestion of a 300 mg dose (14) . 
